Search results for "THROMBOSIS"

showing 10 items of 630 documents

Novel complement C1 inhibitor BSF468248 does not improve brain damage after cortical vein occlusion

2003

BSF468248 is a novel potent complement C1 inhibitor. To determine whether BSF468248 is effective against focal cerebral ischemia, we evaluated the change of cerebral blood flow (CBF) and infarction volume using a photochemically-induced cortical vein occlusion model in rats in blind studies. In 22 Wistar rats, two adjacent cortical veins were occluded by photochemical thrombosis and fiberoptic illumination under controlled anesthesia and ventilation. Just after the occlusion, BSF468248 or physiological saline was administrated. In the low-dose study, a treatment group (n = 7) was administered BSF468248 1 mg/kg bolus and 1 mg/kg continuously for 30 min. The same volume of saline was given to…

MaleCerebral veinsPhotochemistrymedicine.medical_treatmentComplement C1 Inactivator ProteinsRats Sprague-DawleyBolus (medicine)OcclusionmedicineAnimalsRats WistarInfusions IntravenousSalineCerebral Cortexbusiness.industryCerebral InfarctionBlood flowCortical Veinmedicine.diseaseCerebral VeinsThrombosisRatsDisease Models AnimalTreatment OutcomeCerebral blood flowRegional Blood FlowBrain InjuriesCerebrovascular CirculationAnesthesiaIntracranial ThrombosisbusinessOligopeptidesMethods and Findings in Experimental and Clinical Pharmacology
researchProduct

Cluster analysis of mrna expression levels identifies multiple sequential patterns following focal cerebral ischemia

2012

AIM The purpose of this study is to detect gene expression patterns following focal cerebral ischemia. MATERIAL AND METHODS 25 male Wistar rats were divided into control (n = 8) and ischemic (n = 17) groups. In the ischemic group, slowly progressing focal ischemia was simulated by two-vein occlusion with spreading depression (SD) a cortical microinjection of KCl induced. Ischemic tissue was removed at 2, 8, 24, or 72 h postischemia. Using semiquantitative reverse transcription polymerase chain reaction, we investigated mRNA expression levels of 13 representative genes related to cerebral ischemia. Cluster analysis of the gene expression levels was done. RESULTS In the ischemic group, the ex…

MaleCerebral veinsmedicine.medical_specialtyTranscription GeneticPhotochemistryIschemiaNerve Tissue ProteinsReal-Time Polymerase Chain ReactionBioinformaticsPotassium ChlorideCyclin D1Internal medicineGene expressionElectric ImpedancemedicineAnimalsCluster AnalysisRNA MessengerRats WistarCerebral Cortexbusiness.industryCortical Spreading Depressionmedicine.diseaseCerebral VeinsRatsReverse transcription polymerase chain reactionmedicine.anatomical_structureEndocrinologyReal-time polymerase chain reactionIschemic Attack TransientCerebral cortexCortical spreading depressionSurgeryNeurology (clinical)Intracranial ThrombosisbusinessTurkish Neurosurgery
researchProduct

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy

2020

Background Few data are available on the rate and characteristics of thromboembolic complications in hospitalized patients with COVID-19. Methods We studied consecutive symptomatic patients with laboratory-proven COVID-19 admitted to a university hospital in Milan, Italy (13.02.2020–10.04.2020). The primary outcome was any thromboembolic complication, including venous thromboembolism (VTE), ischemic stroke, and acute coronary syndrome (ACS)/myocardial infarction (MI). Secondary outcome was overt disseminated intravascular coagulation (DIC). Results We included 388 patients (median age 66 years, 68% men, 16% requiring intensive care [ICU]). Thromboprophylaxis was used in 100% of ICU patients…

MaleComorbidity030204 cardiovascular system & hematologyBrain Ischemia0302 clinical medicineHospitals UrbanPatient AdmissionRisk FactorsPulmonary angiographyAmbulatory CareThrombophiliaCardiovascular complicationsMyocardial infarctionHospital MortalityAged 80 and overHematologyMiddle AgedPulmonary embolismItaly030220 oncology & carcinogenesisAmbulatoryFemaleCoronavirus InfectionsVenous thromboembolismmedicine.medical_specialtyAcute coronary syndromeCritical CarePneumonia ViralArterial Occlusive DiseasesDisseminated intravascular coagulationThrombophiliaArticle03 medical and health sciencesInternal medicineIntensive caremedicineHumansAcute Coronary SyndromeMortalityHospitals TeachingPandemicsAgedRetrospective Studiesbusiness.industryCoronary ThrombosisAnticoagulantsCOVID-19Retrospective cohort studyLength of Staymedicine.diseaseSARS-CoV2businessPulmonary EmbolismThrombosis Research
researchProduct

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Incidence, risk factors, clinical characteristics and outcomes of deep venous thrombosis in patients with COVID-19 attending the Emergency Department…

2021

Background and importance A higher incidence of venous thromboembolism [both pulmonary embolism and deep vein thrombosis (DVT)] in patients with coronavirus disease 2019 (COVID-19) has been described. But little is known about the true frequency of DVT in patients who attend emergency department (ED) and are diagnosed with COVID-19. Objective We investigated the incidence, risk factors, clinical characteristics and outcomes of DVT in patients with COVID-19 attending the ED before hospitalization. Methods We retrospectively reviewed all COVID patients diagnosed with DVT in 62 Spanish EDs (20% of Spanish EDs, case group) during the first 2 months of the COVID-19 outbreak. We compared DVT-COVI…

MaleDeep veinComorbidity030204 cardiovascular system & hematologyChest pain0302 clinical medicineRisk Factorsrisk factorsclinical characteristicsIncidenceIncidence (epidemiology)Age FactorsVenous ThromboembolismMiddle AgedPulmonary embolismVenous thrombosismedicine.anatomical_structureEmergency MedicineoutcomeFemalemedicine.symptomEmergency Service Hospitalsevere acute respiratory syndrome coronavirus 2Adultmedicine.medical_specialtyRisk Assessment03 medical and health sciencescoronavirus disease 2019Internal medicineThromboembolismmedicineHumanscardiovascular diseasesTromboembolismeAgedRetrospective Studiesdeep venous thrombosisbusiness.industryCOVID-19030208 emergency & critical care medicineRetrospective cohort studyOriginal ArticlesEmergency departmentOdds ratiomedicine.diseaseSpainCase-Control StudiesincidencePulmonary Embolismbusiness
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

Prothrombotic gene variants as risk factors of acute myocardial infarction in young women

2012

Abstract Background Acute myocardial infarction (AMI) in young women represent an extreme phenotype associated with a higher mortality compared with similarly aged men. Prothrombotic gene variants could play a role as risk factors for AMI at young age. Methods We studied Factor V Leiden, FII G20210A, MTHFR C677T and beta-fibrinogen -455G&gt;A variants by real-time PCR in 955 young AMI (362 females) and in 698 AMI (245 females) patients. The data were compared to those obtained in 909 unrelated subjects (458 females) from the general population of the same geographical area (southern Italy). Results In young AMI females, the allelic frequency of either FV Leiden and of FII G20210A was signif…

MaleHomocysteineMyocardial Infarctionlcsh:Medicinegene variantsprothrombotic gene variantsAMIchemistry.chemical_compoundGene FrequencyRisk FactorsgenderMyocardial infarctionMedicine(all)GeneticsYoung AMI Gender AMI Gene variants Mutations Prothrombotic variants Genetic predispositioneducation.field_of_studyprothrombotic variantsbiologyHomozygoteFactor VGeneral MedicineFemaleProthrombinyoung AMIAdultmedicine.medical_specialtyPopulationyoung AMI gender AMI gene variants mutations prothrombotic variants genetic predisposition.Polymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyInternal medicinemedicineFactor V LeidenGenetic predispositionHumansGenetic Predisposition to Diseasecardiovascular diseaseseducationAllele frequencyAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchlcsh:RFactor VThrombosismutationsmedicine.diseasechemistryMethylenetetrahydrofolate reductasebiology.proteinbusinessgenetic predispositionJournal of Translational Medicine
researchProduct

C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association an…

2010

3 Figures. 2 Tables. The online version of this article contains a data supplement.

MaleImmunologySingle-nucleotide polymorphismGenome-wide association studyLocus (genetics)ThrombophiliaBiochemistryPolymorphism Single NucleotideProtein SProtein SRisk FactorsHistocompatibility AntigensMedicineHumansGenetic Predisposition to DiseaseAlleleGeneticsVenous ThrombosisClinical Trials as Topicbiologybusiness.industryC4b-binding proteinComplement C4b-Binding ProteinCase-control studyCell BiologyHematologymedicine.diseasePS-independentprotein (C4BP)Gene Expression RegulationGenetic LociCase-Control Studiesprotein S (PS)biology.proteinFemalebusinessGenome-Wide Association Study
researchProduct

ASSOCIATION OF AN ORGAN TRANSPLANT-BASED APPROACH WITH A DRAMATIC REDUCTION IN POSTOPERATIVE COMPLICATIONS FOLLOWING RADICAL NEPHRECTOMY AND TUMOR TH…

2019

Objectives: Our aim was to determine whether using an organ transplant-based(TB) approach reduces postoperative complications(PCs) following radical nephrectomy(RN) and tumor thrombectomy(TT) in renal cell carcinoma(RCC) patients with level II-IV thrombi. Methods: A total of 390(292 non-TB/98 TB) IRCC-VT Consortium patients who received no preoperative embolization/IVC filter were included. Stepwise linear/logistic regression analyses were performed to determine significant multivariable predictors of intraoperative estimated blood loss(IEBL), number blood transfusions received, and overall/major PC development within 30days following surgery. Propensity to receive the TB approach was contr…

MaleKidney DiseaseVena Cavamedicine.medical_treatment030232 urology & nephrologyLogistic regressionNephrectomyOrgan transplantation0302 clinical medicinePostoperative ComplicationsRenal cell carcinomaInferior vena cavaCancerThrombectomyGeneral MedicineMiddle AgedNephrectomyRenal cell carcinomaKidney NeoplasmsOncologymedicine.vein030220 oncology & carcinogenesisFemaleInferior vena cava; Postoperative complications; Renal cell carcinoma; Surgical technique; Tumor thrombus6.4 SurgeryInferiormedicine.medical_specialtyOncology and CarcinogenesisUrologyIvc filterVena Cava InferiorInferior vena cavaArticle03 medical and health sciencesPostoperative complicationsRare DiseasesBlood lossmedicineHumansBlood TransfusionOncology & CarcinogenesisCarcinoma Renal CellRetrospective Studiesbusiness.industryCarcinomaRenal CellEvaluation of treatments and therapeutic interventionsSurgical techniqueThrombosismedicine.diseasePostoperative complicationTumor thrombusPropensity score matchingSurgerybusinessFollow-Up Studies
researchProduct

Dynamic in vivo Imaging of Microvasculature and Perfusion by Miniaturized Confocal Laser Microscopy

2008

&lt;i&gt;Introduction:&lt;/i&gt; Microvasculature and associated pathologies mandate dynamic imaging. We evaluated a novel miniaturized confocal laser scanning probe for in vivo visualization of blood vessels, blood flow, cell tracking and perfusion in both healthy rodents and disease models.&lt;i&gt; Methods:&lt;/i&gt; The hand-held confocal microscopy system allowed a 500- to 2,400-fold magnification at a dynamically variable imaging depth. Different intravital stains were used alone or in combination for tissue, nuclear, plasma and vascular endothelial cell staining and for blood flow visualization, and targeted staining for individual cell populations. &lt;i&gt;Results:&lt;/i&gt; Precis…

MaleMice Inbred MRL lprPathologymedicine.medical_specialtyMaterials scienceLaser scanningDynamic imagingConfocalCell Communicationlaw.inventionMiceImaging Three-DimensionalIn vivoConfocal microscopylawMicroscopyLeukocytesmedicineAnimalsFluorescent DyesInflammationMicroscopy ConfocalMiniaturizationMicrocirculationBrainEndothelial CellsThrombosisLupus NephritisMice Inbred C57BLDisease Models AnimalMicrovesselsFemaleSurgeryIntracranial ThrombosisGerbillinaePerfusionBlood Flow VelocityPreclinical imagingBiomedical engineeringEuropean Surgical Research
researchProduct